Beneficial Metabolic Effects of Chronic Glipizide in Obese African Americans with Impaired Glucose Tolerance: Implications for Primary Prevention of Type 2 Diabetes

Metabolism: Clinical and Experimental

Volumn 53, Issue 4, 2004, Pages 414-422

  Osei, Kwame ^a   Rhinesmith, Scott ^a   Gaillard, Trudy ^a   Schuster, Dara ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLIPIZIDE; INSULIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; GLUCOSE HOMEOSTASIS; HIGH RISK POPULATION; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN;

EID: 1842479700     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.11.016     Document Type: Article

References (28)

1. King H, Rewers M: Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 16: 157-177, 1993
2. King H, Aubert R, Herman WH: Global burden of diabetes, 1995-2025. Prevalence and numerical estimates and projections. Diabetes Care 21:1414-1433, 1998
3. Harris ML, Flegal KM, Cowie C, et al: Prevalence of diabetes, impaired fasting and impaired glucose tolerance in US Adults. The Third National Health and Nutrition Survey 1988-1994. Diabetes Care 21:518-524, 1998
4. Harris MI, Hadden WC, Knowler WC, et al: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74. Diabetes 6:523-524, 1987
5. Harris MI, Klein RD, Cowie CC, et al: Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A US population study. Diabetes Care 21:1230-1235, 1998
6. DeFronzo RA: The triumvirate, B-cell, muscle, liver; a collusion responsible for NIDDM. Diabetes 37:667-687, 1988
7. Reaven GM, Berstein R, Davis B, et al: Nonketotic diabetes mellitus: Insulin deficiency or insulin resistance. Am J Med 60:80-88, 1976
8. Osei K, Gaillard T, Schuster D: Pathogenetic mechanisms of impaired glucose tolerance and type 2 diabetes in African Americans: Significance of insulin secretion, insulin sensitivity and glucose effectiveness. Diabetes Care 20:398-404, 1997
9. Weyer C, Bogardus C, Mott DM, et al: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes. J Clin Invest 104:787-794, 1999
10. Bergman RN: Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 38:1512-1527, 1989
11. Buchanan TA: Pancreatic beta cell defects in gestational diabetes: Implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 86:989-993, 2001
12. Diabetes Prevention Program Research Group: Reduction in the incident of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:303-403, 2002
13. Tuomillehto J, Lindstrom J, Erickson J, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
14. Buchanan TA, Xiang AH, Peters RK, et al: Preservation of pancreatic beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk in Hispanic women. Diabetes 51:2796-2803, 2002
15. Pan XR, Li G-W, Wang J-X: Effects of diet and exercise in the prevention of NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
16. Osei K, Schuster DP: Ethnic differences in secretion, sensitivity and hepatic extraction of insulin in black and white Americans. Diabet Med 11:755-762, 1994
17. Haffner S, Howard G, Savage PJ, et al: Increased insulin resistance and insulin secretion in nondiabetic African Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes 45:742-747, 1996
18. World Health Organization Study Group: Diabetes Mellitus. Report of WHO Study Group. WHO Technical Report Series No. 772. Geneva, Switzerland, WHO, 1985
19. Segal KR, Loan MC, Fitzgerald PL, et al: Lean body mass estimation by electrical impedance analysis: A four-site cross-validation study. Am J Clin Nutr 47:4-17, 1988
20. Bergman RN, Prager R, Volund A, et al: Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79:790-800, 1987
21. Kahn SE, Prager RL, McCullough DK, et al: The contribution of insulin dependent and insulin-independent glucose uptake to intravenous glucose tolerance healthy human subjects. Diabetes 43:587-592, 1994
22. United Kingdom Prospective Diabetes Study. Intensive blood glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS) 34. Lancet 32:854-865, 1998
23. Greenfield MS, Doreen L, Rosenthal M, et al: Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes. Diabetes 31:307-312, 1982
24. Kirkland KI, Melinda FK, Mowinckel P, et al: Long-term randomized placebo-controlled double blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 5 months. Diabetes Care 17:45-49, 1991
25. Ravanam A, Jeffery J, Nehlawi M, et al: Improvement of glucose-primed intravenous glucose tolerance and correction of acute insulin decrement by glipizide in type II diabetes. Metabolism 40:1173-1177, 1991
26. Simonson DC, Kouradis IA, Feinglos M, et al: Efficacy, safety, and doseresponse characteristics of glipizide gastrointestinal therapeutic system on glucose control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo controlled studies. Diabetes Care 20:597-606, 1997
27. Sator G, Schenstein B, Carlson S: Ten year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet. Diabetes 29:41-49, 1980
28. Banerji MA, Chaiken RL, Lebowitz HE: Prolongation of near normal glycemic remission in black NIDDM subjects with chronic low dose sulfonylurea treatment. Diabetes 44:466-470, 1991